Lack of major olfactory dysfunction in MPTP-induced parkinsonism.
The olfactory function of 6 patients whose parkinsonism was the result of intravenous administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was compared to that of 12 age-matched patients with idiopathic Parkinson's disease (PD) and 10 age-matched normal control subjects. Unlike their PD counterparts, the olfactory test scores of patients with MPTP-induced parkinsonism did not differ significantly from those of control subjects. These findings suggest that MPTP-induced parkinsonism, unlike idiopathic PD, is unaccompanied, on average, by major alterations in the ability to smell.
Doty
R L
RL
Department of Otorhinolaryngology: Head and Neck Surgery, University of Pennsylvania, Philadelphia.
Singh
A
A
Tetrud
J
J
Langston
J W
JW
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects*; D000328:Adult; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010300:Parkinson Disease / Q000503:physiopathology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D012684:Sensory Thresholds; D012903:Smell
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine